| 1 |
-
Levodopa: A novel therapeutic prospect for liver disease
-
2/12/2026 11:20:20 AM | Browse: 57 | Download: 189
|
| 2 |
-
Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients
-
12/26/2025 10:27:34 AM | Browse: 76 | Download: 319
|
| 3 |
-
Application of stem cells in the precise diagnosis and treatment of liver diseases
-
12/10/2025 7:48:06 AM | Browse: 68 | Download: 218
|
| 4 |
-
OraQuick hepatitis C virus self-test: A new frontier in hepatitis C screening
-
9/25/2025 9:22:02 AM | Browse: 137 | Download: 248
|
| 5 |
-
Micro RNAs as a potential biomarker for predicting liver fibrosis severity in hepatitis C virus affected patients
-
6/23/2025 7:18:41 AM | Browse: 137 | Download: 755
|
| 6 |
-
Gut feeling gone wrong: Tangled relationship between disorders of gut-brain interaction and liver disease
-
5/27/2025 7:04:47 AM | Browse: 92 | Download: 473
|
| 7 |
-
Mixed lineage kinase domain-like protein in liver diseases: Cell-type-specific functions and dual roles
-
4/11/2025 2:19:31 AM | Browse: 92 | Download: 487
|
| 8 |
-
Targeting mixed lineage kinase domain-like protein's non-necroptosis role: A new horizon in anti-inflammatory therapy for alcoholic liver disease
-
4/2/2025 10:54:11 AM | Browse: 90 | Download: 476
|
| 9 |
-
Gut microbiota in the development and progression of chronic liver diseases: Gut microbiota-liver axis
-
3/26/2025 4:06:52 AM | Browse: 134 | Download: 408
|
| 10 |
-
Current impact in the treatment of advanced hepatocellular carcinoma: The challenge remains
-
2/14/2025 10:33:25 AM | Browse: 144 | Download: 449
|
| 11 |
-
Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders
-
12/30/2024 6:47:30 AM | Browse: 100 | Download: 493
|
| 12 |
-
Diagnostic value of tissue plasminogen activator-inhibitor complex in sepsis-induced liver injury: A single-center retrospective case-control study
-
11/6/2024 9:50:59 AM | Browse: 194 | Download: 940
|
| 13 |
-
Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis
-
10/31/2024 7:40:50 AM | Browse: 156 | Download: 802
|
| 14 |
-
Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease
-
10/16/2024 6:29:25 AM | Browse: 176 | Download: 555
|
| 15 |
-
Interleukin-mediated therapies in liver diseases and comorbidity effects
-
7/26/2024 10:33:29 AM | Browse: 227 | Download: 709
|
| 16 |
-
Immunological crossroads: The intriguing dance between hepatitis C and autoimmune hepatitis
-
6/20/2024 3:42:22 AM | Browse: 206 | Download: 629
|
| 17 |
-
Revolutionizing disease diagnosis and management: Open-access magnetic resonance imaging datasets a challenge for artificial intelligence driven liver iron quantification
-
6/4/2024 3:55:01 PM | Browse: 149 | Download: 725
|
| 18 |
-
Dynamic changes and clinical value of lipocalin 2 in liver diseases caused by microbial infections
-
2/27/2024 11:58:45 AM | Browse: 254 | Download: 1036
|
| 19 |
-
Liver disease epidemiology and burden in patients with alterations in plasma protein metabolism: German retrospective insurance claims analysis
-
10/24/2023 8:39:24 AM | Browse: 331 | Download: 1099
|
| 20 |
-
Advances in application of novel magnetic resonance imaging technologies in liver disease diagnosis
-
7/26/2023 11:55:37 AM | Browse: 331 | Download: 1003
|
| 21 |
-
COVID-19-induced liver injury in infants, children, and adolescents
-
6/8/2023 9:24:51 AM | Browse: 468 | Download: 1175
|
| 22 |
-
Liver involvement in patients with COVID-19 infection: A comprehensive overview of diagnostic imaging features
-
2/6/2023 12:22:17 PM | Browse: 527 | Download: 1124
|
| 23 |
-
Iron as a therapeutic target in chronic liver disease
-
1/20/2023 1:48:21 PM | Browse: 369 | Download: 1160
|
| 24 |
-
Machine learning approaches using blood biomarkers in non-alcoholic fatty liver diseases
-
6/28/2022 9:38:07 AM | Browse: 774 | Download: 1832
|
| 25 |
-
COVID-19 and liver diseases, what we know so far
-
4/30/2022 5:08:22 AM | Browse: 614 | Download: 1330
|
| 26 |
-
COVID-19, liver dysfunction and pathophysiology: A conceptual discussion
-
2/9/2022 7:25:27 AM | Browse: 684 | Download: 1603
|
| 27 |
-
Emerging artificial intelligence applications in liver magnetic resonance imaging
-
10/27/2021 7:14:11 AM | Browse: 647 | Download: 1565
|
| 28 |
-
Liver and COVID-19: From care of patients with liver diseases to liver injury
-
10/22/2021 1:53:28 PM | Browse: 658 | Download: 1521
|
| 29 |
-
Factors predicting futility of liver transplant in elderly recipients: A single-center experience
-
10/14/2021 9:37:43 AM | Browse: 849 | Download: 1873
|
| 30 |
-
Malnutrition and liver disease in a developing country
-
8/10/2021 6:48:42 AM | Browse: 773 | Download: 1821
|
| 31 |
-
Liver dysfunction and SARS-CoV-2 infection
-
7/12/2021 12:42:13 AM | Browse: 840 | Download: 1667
|
| 32 |
-
Viscoelastic tests in liver disease: where do we stand now?
-
6/18/2021 5:06:16 AM | Browse: 717 | Download: 1677
|
| 33 |
-
Role of bile acids in liver diseases mediated by gut microbiome
-
6/8/2021 10:51:03 AM | Browse: 733 | Download: 2064
|
| 34 |
-
Bile acid indices as biomarkers for liver diseases I: Diagnostic markers
-
4/16/2021 10:13:42 AM | Browse: 760 | Download: 2026
|
| 35 |
-
COVID-19 and co-morbidities of hepatic diseases in a global perspective
-
3/30/2021 7:03:44 AM | Browse: 738 | Download: 1736
|
| 36 |
-
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
-
12/21/2020 12:21:52 PM | Browse: 934 | Download: 1626
|
| 37 |
-
Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis
-
11/24/2020 12:41:21 PM | Browse: 830 | Download: 2517
|
| 38 |
-
Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
-
9/21/2020 4:02:08 PM | Browse: 888 | Download: 2146
|
| 39 |
-
Progress of intravoxel incoherent motion diffusion-weighted imaging in liver diseases
-
8/6/2020 9:52:05 AM | Browse: 954 | Download: 1900
|
| 40 |
-
Role of γδT cells in liver diseases and its relationship with intestinal microbiota
-
5/28/2020 1:08:01 PM | Browse: 1171 | Download: 2328
|
| 41 |
-
Role of spleen tyrosine kinase in liver diseases
-
3/14/2020 3:03:29 PM | Browse: 1150 | Download: 1898
|
| 42 |
-
Study on serum amyloid A levels in patients with liver diseases
-
11/21/2019 8:40:16 AM | Browse: 1334 | Download: 2613
|
| 43 |
-
Organoids of liver diseases: From bench to bedside
-
4/25/2019 3:13:57 AM | Browse: 1118 | Download: 2226
|
| 44 |
-
Extreme hyperbilirubinemia: An indicator of morbidity and mortality in sickle cell disease
-
3/27/2019 10:37:20 AM | Browse: 1283 | Download: 2233
|
| 45 |
-
Dental pulp cell bank as a possible future source of individual hepatocytes
-
10/27/2018 4:40:10 AM | Browse: 1363 | Download: 1940
|
| 46 |
-
Alkaline sphingomyelinase (NPP7) in hepatobiliary diseases: A field that needs to be closely studied
-
3/4/2018 12:36:47 PM | Browse: 1231 | Download: 1622
|
| 47 |
-
Genetic variants of interferon regulatory factor 5 associated with chronic hepatitis B infection
-
1/14/2018 5:07:58 AM | Browse: 1420 | Download: 1889
|
| 48 |
-
Effect of silymarin on biochemical indicators in patients with liver disease: systematic review with meta-analysis
-
7/20/2017 10:12:50 AM | Browse: 1731 | Download: 2380
|
| 49 |
-
Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis
-
6/14/2017 9:25:57 AM | Browse: 1295 | Download: 2236
|
| 50 |
-
MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis b- and c-related-hepatocellular-carcinoma
-
4/12/2016 1:04:00 PM | Browse: 1765 | Download: 3378
|
